Clinical trials: Alpha-Synucleinopathy, open to volunteers
Parkinson´s Disease, REM Sleep Behavior Disorder (iRBD)
The Swedish BioFINDER Sleep Study
BioFINDER-Sleep study was established in 2021 and will include patients with early Parkinson´s disease (PD) and persons with iRBD to provide essential insights into the underlying mechanisms of the progressive neurodegenerative…
- Conditions
- Parkinson´s Disease, REM Sleep Behavior Disorder (iRBD), Lewy Body Disease, Synucleinopathy
- Trial name
- NCT07533799
- Testing
- Dopamine transporter PET scan with [18F]FE-PE2I, Magnetic resonance imaging (MRI), [123I] MIBG scintigraphy of the heart
- Where
- Sweden
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
REM Sleep Behavior Disorder
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
This is a phase 2 study to assess the ability of adalimumab as compared to placebo to reduce or prevent progression of synuclein-related neurodegeneration in persons with idiopathic REM Sleep Behavior Disorder (RBD).
- Trial name
- PRISMS (NCT06996652)
- Testing
- Adalimumab
- Where
- 18 sites in United States, Canada
- Volunteers
- 108 people
- Sponsor
- Yale University
Alpha Synuclein Pathology, Alpha-Synuclein
Alpha-Synuclein PET/CT in Various α-Syn-Related Disease
To evaluate the potential usefulness of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various α-Syn-related disease patients.
- Conditions
- Alpha Synuclein Pathology, Alpha-Synuclein, Parkinson Disease
- Trial name
- NCT06949670
- Testing
- 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06
- Where
- 3 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
α-synucleinopathy
A Registered Cohort Study on α-Synucleinopathy
α-Synucleinopathy is a cluster of neurodegenerative disease with motor and non-motor symptom. The data to be collected is intended to help healthcare providers make important medical decisions concerning α-synucleinopathy…
- Trial name
- NCT05527067
- Testing
- Data collection
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Parkinson Disease
Brain Training to Improve Balance in Parkinson's Disease
People living with Parkinson's (PwP) rank balance problems amongst the most disabling symptom. Over time, balance function continues to decline and PwP go on to fall, affecting between 45-68% of PwP.
- Trial name
- NCT05986643
- Testing
- Exergame+Neurofeedback, Exergame [alone]
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University of Leicester
Parkinson Disease (PD), MSA - Multiple System Atrophy
Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase
This is an open-label, single-center Phase 1 study evaluating the safety, tolerability, and test-retest characteristics of [11C]MODAG-005, an investigational positron emission tomography/computed tomography (PET/CT) radioligand…
- Conditions
- Parkinson Disease (PD), MSA - Multiple System Atrophy, Healthy Adult Participants
- Trial name
- PIOSA (NCT07640542)
- Testing
- [11C]MODAG-005
- Where
- Germany
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
PARKINSON DISEASE (Disorder), Parkinson
Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder
The goal of this observational study is to learn whether tissue samples taken from the colon during routine colonoscopy can detect signs of Parkinson's disease or REM Sleep Behavior Disorder (RBD).
- Conditions
- PARKINSON DISEASE (Disorder), Parkinson, Parkinson s Disease, Parkinson Disease
- Trial name
- Syn-G (NCT07217054)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- CND Life Sciences
Parkinson Disease, Prodromal Stage
Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity
α-Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are the second most common neurodegenerative diseases.
- Conditions
- Parkinson Disease, Prodromal Stage, Neurodegenerative Diseases, Basal Ganglia Diseases
- Trial name
- ALPHA-FIT (NCT07324330)
- Testing
- Increase of physical activity volume and intensity with the use of a motivational smartphone application
- Where
- Germany
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Lewy Body Disease
Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease
The goal of the study is to assess if learning one's Lewy Body Dementia (LBD) biomarker test result impacts longitudinal psychosocial and behavioral responses and to identify factors that moderate and mediate these outcomes.
- Trial name
- NCT07646652
- Testing
- LBD Biomarker Education and Disclosure
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Stanford University
REM Sleep Behavior Disorder, Parkinson Disease
North American Prodromal Synucleinopathy Consortium Stage 2
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
- Conditions
- REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies
- Trial name
- NAPS2 (NCT05826457)
- Where
- 9 sites in United States, Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Synucleinopathy, Parkinson's Disease
Tenapanor in Synucleinopathy-Related Constipation
Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation
- Trial name
- NCT06460038
- Testing
- Tenapanor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cedar Valley Digestive Health Center
Parkinson's Disease (PD), GBA1 Parkinson Disease
Understanding Alpha-Synuclein Spread in Parkinson's Disease Through Blood Biomarkers and Neuroimaging
The project aims to investigate how abnormal accumulation of alpha synuclein and its interaction with tau influence brain function across the Parkinson's disease (PD) spectrum, with particular focus on individuals carrying GBA1…
- Conditions
- Parkinson's Disease (PD), GBA1 Parkinson Disease, REM Sleep Behavior Disorder (iRBD)
- Trial name
- SYNchronPD (NCT07474779)
- Testing
- brain imaging, blood draw, Skin biopsy
- Where
- 2 sites in Italy
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University of Pavia
Cognitive Dysfunction, Lewy Body Disease
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily…
- Conditions
- Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
- Trial name
- NCT07589595
- Testing
- Donanemab
- Where
- 72 sites in United States, Japan and 2 more
- Volunteers
- 350 people
- Sponsor
- Eli Lilly and Company
Parkinsons Disease (PD), Healthy Elderly Volunteers
MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD)
This is a single-center, open-label clinical study designed to evaluate alpha-synuclein (ASYN) deposition in the brain of participants with Parkinson's disease (PD), as compared with healthy elderly (HE) participants.
- Trial name
- NCT07880379
- Testing
- [¹⁸F]MK-0947
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- XingImaging, LLC
REM Sleep Behavior Disorder, Parkinson Disease
North American Prodromal Synucleinopathy Consortium
This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
- Conditions
- REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Disease, Dementia With Lewy Bodies
- Trial name
- NAPS (NCT03623672)
- Where
- 10 sites in United States, Canada
- Volunteers
- 500 people
- Sponsor
- Washington University School of Medicine
Parkinsons Disease (PD)
Metformin in Parkinson's Disease: Safety and Efficacy
This study will evaluate whether metformin when it will be given to patients with Parkinson's disease along with standard therapy (levodopa carbidopa) will improve motor symptoms and decreases levels of alpha synuclein and MDA in…
- Trial name
- MET-PD (NCT07806019)
- Testing
- Metformin 500mg
- Volunteers
- 70 people
- Sponsor
- Jinnah Medical & Dental College
Alzheimer Disease, Frontotemporal Dementia
Proteinopathies Expression in Skin of Neurodegenerative Disorders
The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 [TDP43]) in skin biopsies of…
- Conditions
- Alzheimer Disease, Frontotemporal Dementia, Parkinson Disease, Atypical Parkinsonism
- Trial name
- NCT06528964
- Testing
- Immunohistochemistry and immunofluorescence
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de San Luis Potosí
Multiple System Atrophy, Parkinson's Disease
Prospective Multicenter Registry Study of Multiple System Atrophy in China
Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease characterized by variable combinations of parkinsonism, cerebellar ataxia, and autonomic dysfunction.
- Conditions
- Multiple System Atrophy, Parkinson's Disease, Atypical Parkinsonism
- Trial name
- MSA Registry S (NCT07644013)
- Where
- China
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Parkinson Disease
Parkinson's Disease Biomarkers in Nerve Cells in the Gut
Parkinson's disease affects all the nerve cells in the body, including the ones in the gut. The gut contains its own nervous system, the enteric nervous system, and can be thought of as a "second brain".
- Trial name
- PD-ENS (NCT05347407)
- Testing
- Colonoscopy
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Parkinson Disease
Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study
The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year.
- Trial name
- PASS-PD (NCT04724941)
- Testing
- No intervention
- Where
- Germany
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University Hospital Schleswig-Holstein